NCT07451652RecruitingPhase 2
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 13 Feb 2026
- Start date
- 17 Mar 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07451652
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- From 17 Mar 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who have already received an autologous o allogeneic stem cell transplantation
Other illness
- Active bacterial, viral or fungal infection
- Subjects with end-stage failure
Other
- Subjects with other active neoplasias
Who the study is looking for
- Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
- ECOG 0-2
- Women of reproductive age who agree on getting a contraceptive method
- Subjects who fulfill Lugano´s criteria for disease activity
- Subjects who voluntarily accept to participate in this study
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Dr. Jose Eleuterio González Coordinator of this site? Confirm its status | Monterrey | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.